Advanced Enzyme
Specialty Chemicals · ADVENZYMES
Small CapBasic MaterialsMature Stable
Mukund Kabra
Whole-time Director · Pragmatic
Company DNA
Hierarchical
About
Advanced Enzyme is a Small Cap company in the Basic Materials sector, listed on NSE as ADVENZYMES. With a market cap of ₹3K Cr and revenue of ₹637 Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Promoter-family dominated board with long-standing tenure and systematic operations characteristic of mature specialty chemical firms. Its strategic mandate: To break out of stagnant growth, the company must innovate its specialized bio-catalyst portfolio to capture new global market segments.
FAQ
What kind of company is Advanced Enzyme?
Advanced Enzyme is a Small Cap Basic Materials company (ADVENZYMES) in the Mature Stable phase with a market cap of ₹3K Cr. It is classified as Hierarchical in culture.
What is Advanced Enzyme's culture and work environment like?
Advanced Enzyme has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Promoter-family dominated board with long-standing tenure and systematic operations characteristic of mature specialty chemical firms.
Who leads Advanced Enzyme?
Advanced Enzyme is led by Mukund Kabra (Whole-time Director), a Pragmatic leader with 32 years of experience.
What are Advanced Enzyme's financials?
Advanced Enzyme reported revenue of ₹637 Cr in FY25 with a 5-year revenue CAGR of 6.4%. Operating margin: 25.2%. Market cap: ₹3K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleMature Stable
Promoter-family dominated board with long-standing tenure and systematic operations characteristic of mature specialty chemical firms.
Mandate
To break out of stagnant growth, the company must innovate its specialized bio-catalyst portfolio to capture new global market segments.
To break out of stagnant growth, the company must innovate its specialized bio-catalyst portfolio to capture new global market segments.
Financials
Revenue FY25₹637 Cr
PAT FY25₹131 Cr
Rev CAGR 5Y6.4%
OPM25.2%
NPM20.6%
ROE9.2%
ROCE10.5%
P/E20.4
Fwd P/E17.9
P/B2.1
D/E2.3
Mkt Cap₹3K Cr
Promoter57.1%
Institutional18.8%
Similar Culture
Could You Lead Advanced Enzyme?
Take the Genome Benchmark →